Junshi Biosciences (01877): First patient dosed in Phase III clinical trial of JS203 combined with chemotherapy for the treatment of diffuse large B-cell lymphoma

Zhitong Finance APP News, Junshi Biosciences (01877) announced that the company's product recombinant humanized anti-CD20 and CD3 bispecific antibody (code: JS203) combined with chemotherapy versus rituximab combined with chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) has completed first patient dosing in a randomized, open-label, multicenter Phase III clinical study. This study is the first registrational clinical study of JS203.